Same Mutation, Different Fate
When MRD testing evolves from a numerical readout into a definition of clonal behavior, it becomes what clinicians have needed all along: a tool that informs action, not just detection.
The power of Next Generation Sequencing in management of the pandemic and future outbreaks
The Covid-19 pandemic has brought a laser focus to the critical and immediate need for next-generation sequencing tools that can generate invaluable data for not only identifying emerging variants but for understanding the functional and epidemiological consequences of variant-specific mutations.
The Power of One: Redefining Healthcare with an AI-Driven Unified Platform
In a landscape where complexity has long been the norm, the power of one lies not just in unification, but in intelligence and automation.
CMS to cover next-generation sequencing for inherited breast, ovarian cancers
Under the decision, Medicare patients with inherited cancer mutations such as BRCA will receive coverage for NGS testing. Drugs that treat BRCA-mutated breast and ovarian cancers include AstraZeneca's Lynparza and Pfizer's Talzenna.
FTC moves to block Illumina’s $1.2B acquisition of PacBio
Federal regulators said they would seek to block the acquisition deal amid concerns that Illumina was seeking to eliminate PacBio as a competitor in the next-generation sequencing space.
FDA green lights next-gen sequencing platform for drug-resistant HIV
The agency announced it had authorized Vela Diagnostics' Sentosa SQ HIV Genotyping Assay, designed to help healthcare providers tailor antiviral therapy based on the presence of viral resistance mutations.
PierianDx raises $27M in Series B to ‘democratize’ next-generation sequencing
The startup describes its software as providing clinical labs with more streamlined and accurate analysis, interpretation and reporting for accelerating personalized medicine programs.
presented by
RCM Outsourcing: Balancing Human Expertise & Smart Technology
Greenway Health blends smart technology with human expertise to elevate revenue cycle.
Foundation Medicine, Novartis partner up on companion diagnostics in oncology
The partnership will also enable Foundation Medicine to move into ex-US markets like Japan, where it is working with drugmaker Chugai.
Karius’ NGS test for infections shows high sensitivity in pilot study
The study, conducted with St. Jude Children's Research Hospital, showed a 78 percent predictive sensitivity two days before the onset of infection.
FDA approves first NGS test to detect minimal residual disease in two blood cancers
In a first, the agency approved Adaptive Biotechnologies' clonoSEQ assay to detect MRD in acute lymphoblastic leukemia and multiple myeloma, a measure that can predict risk of relapse.
What ever happened to the NantHealth-Independence Blue Cross sequencing partnership?
In January 2016, Independence Blue Cross and NantHealth announced the nation's first coverage for a whole genome sequencing and proteome molecular diagnostic platform, but it's mostly slipped under the radar since then. What's going on?
presented by
Enhanced Direct Enrollment: Georgia Access and the Power of Partnership
Across the nation, state-based health insurance exchanges are searching for ways to better serve their communities while making enrollment easier, more personal, and more accessible for everyone.
Global market for cancer biomarkers set to reach $20.48 billion in four years
Forecast of significant growth in market comes after Roche acquired remaining stake in Foundation Medicine last month.
Strata Oncology scores $26 million for large-scale next-generation sequencing
The company plans to bring NGS to health systems lacking the ability to perform it internally.
Merck, Foundation Medicine to build companion diagnostics for Keytruda
Companies to create tests for tissue-agnostic MSI-H and dMMR cancers using Foundation's next-generation sequencing platform.
Grail nets $300 million from Chinese investors in Series C round
Next-generation sequencing firm plans to present data on its gargantuan genomics study at ASCO next month.
5 snippets from Illumina’s latest earnings call
The leader of the sequencing world is ticking over nicely with sales and revenue, according to Tuesday's earnings call. But what's happening behind the scenes? Here we take a look at five trends shaping the future of the company.